Phase 3 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with stomach (gastric) or gastroesophageal junction cancer confirmed by a tissue or cell sample, where the cancer type is adenocarcinoma.
• People whose cancer has spread to other parts of the body or has grown in a way that makes surgery not possible.
• People whose cancer got worse during or after a first round of treatment that included certain chemotherapy drug combinations (platinum with fluoropyrimidine, or platinum with taxane).
• People who are willing to provide a tumour tissue sample for a specific protein (PD-L1) test.
• People whose HER2 status (a protein that can affect cancer growth) has already been tested, and — if the result was positive — who have already received a treatment that included trastuzumab (a targeted therapy for HER2-positive cancer).
• People with a general health and activity level rated as 0 or 1 on a standard scale used by doctors (meaning fully active or able to carry out light activity).
• People with a life expectancy of more than 12 weeks, as assessed by their doctor.
• People who are willing to sign the trial's consent forms.
• People whose blood tests show that bone marrow, liver, and kidney function are at an acceptable level.

Who may not be able to join:

• People whose stomach cancer is of a squamous cell or undifferentiated type (specific cancer subtypes different from adenocarcinoma).
• People with active cancer spread to the brain or spinal fluid.
• People with an active autoimmune disease (where the immune system attacks the body), with some exceptions — people with well-controlled type 1 diabetes on a stable insulin dose, people with an underactive thyroid managed only with hormone replacement, or people with certain skin conditions (such as eczema, vitiligo, or psoriasis) that do not need systemic (whole-body) treatment and have not significantly worsened in the past year may still be considered (confirm with trial site).
• People with significant heart or blood vessel disease that is clinically concerning.
• People with high blood pressure that cannot be controlled with blood pressure medications.
• People who have had a bleeding event in the digestive tract in the past 3 months, or who have clear signs suggesting a high risk of such bleeding.
• People who have experienced a blood clot or stroke-related event — such as a stroke, mini-stroke, brain bleed, deep vein thrombosis, or pulmonary embolism — within the 6 months before entering the trial.
• People who have previously been treated with certain immune checkpoint therapies (anti-PD-1 or anti-PD-L1 antibodies, or anti-CTLA-4 antibodies) or a specific type of targeted therapy called a VEGFR small molecule inhibitor.
• People who have had chemotherapy, radiation, or surgery within 4 weeks before starting the trial, or who still have unresolved side effects above a mild level from previous treatment.

Important: Always verify eligibility with the trial site directly before applying.